Abstract
Purpose
Not only is the expression of CXCR4 on breast cancers a key determinant of tumor metastasis, CXCL12 exhibiting peak levels of constitutive expression in organs representing the first destinations of cancer metastasis, but is proposed to be also essential for the organ-specific metastatic process.
Methods
In this study, the expressions of CXCR4 and CXCL12 were investigated using quantitative RT-PCR and immunohistochemistry in samples of 63 primary breast carcinomas and 20 normal breast tissues. Using methylation-specific PCR, we also analyzed the methylation status of CXCL12.
Results
Both up-regulation of CXCR4 and down-regulation of CXCL12 were observed in primary breast carcinomas. Over-expression of CXCR4 mRNA was significantly related to lymph node metastasis status and strong Her-2 expression, while decreased expression of CXCL12 mRNA was significantly associated with positive lymph node metastasis and estrogen receptor negativity. Methylation-specific PCR showed that 52.4% of breast tumors were hypermethylated in the CXCL12 promoter region. The expression levels of DNA methyltransferase (DNMT) 1 and DNMT3B were significantly higher in the CXCL12-methylated breast carcinomas than in the CXCL12-unmethylated ones.
Conclusions
In summary, DNA hypermethylation of CXCL12 plays an important role in the down-regulation of CXCL12 expression in breast carcinomas. Cancer cells lacking expression of CXCL12, but maintaining over-expression of CXCR4, can selectively spread to target organs in which the ligand is highly secreted.
Similar content being viewed by others
Abbreviations
- CT :
-
Threshold cycle
- CXCR4:
-
CXC chemokine receptor-4
- CXCL12:
-
CXC chemokine ligand-12
- DNMT:
-
DNA methyltransferase
- ER:
-
Estrogen receptor
- GPCR:
-
G-protein coupled receptor
- MSP:
-
Methylation-specific polymerase chain reaction
- PR:
-
Progesterone receptor
- SDF-1:
-
Stromal cell-derived factor-1
References
Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A et al (2006) Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17:945–951. doi:10.1093/annonc/mdl053
Arya M, Ahmed H, Silhi N, Williamson M, Patel HR (2007) Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 28:123–131. doi:10.1159/000102979
Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL et al (2003) Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 63:1969–1974
Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9:2395–2402. doi:10.1093/hmg/9.16.2395
Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR (2006) CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 6:48. doi:10.1186/1471-2407-6-48
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572. doi:10.1038/nrc865
Davis DA, Singer KE, De La Luz Sierra M, Narazaki M, Yang F, Fales HM et al (2005) Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 105:4561–4568. doi:10.1182/blood-2004-12-4618
Girault I, Tozlu S, Lidereau R, Bièche I (2003) Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 9:4415–4422
Grunau C, Clark SJ, Rosenthal A (2001) Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 29:E65. doi:10.1093/nar/29.13.e65
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G et al (2006) Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 56:450–458. doi:10.1016/j.neures.2006.09.006
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549. doi:10.1016/S1535-6108(03)00132-6
Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG (2005) Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7:R402–R410. doi:10.1186/bcr1022
Kato M, Kitayama J, Kazama S, Nagawa HBB (2003) Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5:R144–R150. doi:10.1186/bcr627
Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C et al (2006) Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244:113–120. doi:10.1097/01.sla.0000217690.65909.9c
Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S et al (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6:3530–3535
Kwon YM, Park JH, Kim H, Shim YM, Kim J, Han J et al (2007) Different susceptibility of increased DNMT1 expression by exposure to tobacco smoke according to histology in primary non-small cell lung cancer. J Cancer Res Clin Oncol 133:219–226. doi:10.1007/s00432-006-0160-2
Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3:85–94. doi:10.1023/A:1018778403001
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408. doi:10.1006/meth.2001.1262
Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238:30–41. doi:10.1016/j.canlet.2005.06.021
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al (2001) Involvement of chemokine receptors in breast cancer metastases. Nature 410:50–56. doi:10.1038/35065016
Robertson KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20:3139–3155. doi:10.1038/sj.onc.1204341
Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S et al (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62:5930–5938
Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z (2006) Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346:252–258. doi:10.1016/j.bbrc.2006.05.110
Siedlecki P, Zielenkiewicz P (2006) Mammalian DNA methyltransferases. Acta Biochim Pol 53:245–256
Sowińska A, Jagodzinski PP (2007) RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines. Cancer Lett 255:153–159. doi:10.1016/j.canlet.2007.04.004
Sutton A, Friand V, Brulé-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O et al (2007) Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 5:21–33. doi:10.1158/1541-7786.MCR-06-0103
Valenzuela-Fernández A, Planchenault T, Baleux F, Staropoli I, Le-Barillec K, Leduc D et al (2002) Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem 277:15677–15689. doi:10.1074/jbc.M111388200
Waha A, Güntner S, Huang TH, Yan PS, Arslan B, Pietsch T et al (2005) Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 7:193–199. doi:10.1593/neo.04490
Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB (2006) Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 25:4986–4997. doi:10.1038/sj.onc.1209505
Wendt MK, Cooper AN, Dwinell MB (2008) Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 27:1461–1471. doi:10.1038/sj.onc.1210751
World Health Organisation (1981) International histological classification of tumours No. 2. Histological typing of breast tumours, 2nd edn. World Health Organisation, Geneva
Yang X, Yan L, Davidson NE (2001) DNA methylation in breast cancer. Endocr Relat Cancer 8:115–127. doi:10.1677/erc.0.0080115
Zlotnik A (2006) Chemokines and cancer. Int J Cancer 119:2026–2029. doi:10.1002/ijc.22024
Acknowledgments
We thank the staff of the Breast Cancer Center, Shandong Cancer Hospital and Institute for assistance in patient care and specimen collection. Written consent for publication was obtained from the patients or their relatives. Support was provided by the Natural Science Foundation of Shandong, 2006ZRC03115 and Y2005C39. This study was also supported by the National High Technology Research and Development Program of China (863 Program), 2007AA02Z437.
Conflict of interest statement
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Wei Zhou and Zheng Jiang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zhou, W., Jiang, Z., Liu, N. et al. Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol 135, 91–102 (2009). https://doi.org/10.1007/s00432-008-0435-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0435-x